{
    "clinical_study": {
        "@rank": "154937", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Compare the efficacy of hydroxyurea with or without clotrimazole in terms of limiting\n      the severity of anemia and the rate of hemolysis in patients with sickle cell anemia."
        }, 
        "brief_title": "Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia", 
        "condition": "Sickle Cell Anemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Sickle Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized study.  Patients are randomized to one of two\n      treatment arms.\n\n      Arm I:  Patients receive oral hydroxyurea and oral clotrimazole daily for 12 months.\n\n      Arm II:  Patients receive oral hydroxyurea daily for 12 months. Patients are followed at 6\n      weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Diagnosis of sickle cell anemia confirmed by hemoglobin electrophoresis\n\n        Received hydroxyurea for at least 6 months On a stable dose for at least 3 months\n        Tolerating dose of at least 5 mg/kg/day\n\n        --Prior/Concurrent Therapy--\n\n        Chemotherapy:\n\n          -  No other concurrent antisickling agent\n\n        Other: No concurrent drug that may interact with or influence the metabolism of\n        hydroxyurea or clotrimazole\n\n        --Patient Characteristics--\n\n        Hematopoietic: WBC at least 4000/mm3 Platelet count at least 150,000/mm3 Hemoglobin less\n        than 11 g/dL\n\n        Hepatic: AST/ALT no greater than 100 units/L\n\n        Renal: Creatinine no greater than 1.5 mg/dL\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n          -  No prior adverse reaction to hydroxyurea or clotrimazole\n\n          -  No recent or progressive neurologic dysfunction"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "20", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004492", 
            "org_study_id": "199/14273", 
            "secondary_id": "UNCCH-FDR001531"
        }, 
        "intervention": [
            {
                "intervention_name": "clotrimazole", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "hydroxyurea", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clotrimazole", 
                "Miconazole", 
                "Hydroxyurea"
            ]
        }, 
        "keyword": [
            "genetic diseases and dysmorphic syndromes", 
            "hematologic disorders", 
            "rare disease", 
            "sickle cell anemia"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "contact": {
                "last_name": "Eugene Paul Orringer", 
                "phone": "919-843-9486"
            }, 
            "facility": {
                "address": {
                    "city": "Chapel Hill", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27599-7070"
                }, 
                "name": "University of North Carolina School of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "University of North Carolina", 
            "last_name": "Eugene Paul Orringer", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004492"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "University of North Carolina", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "October 1999", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2001"
    }, 
    "geocoordinates": {
        "University of North Carolina School of Medicine": "35.913 -79.056"
    }
}